Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Arrhythmia prophylaxis: Long-term suppressive medication.

R R Lovell

    Circulation
    |December 1, 1975
    PubMed
    Summary
    This summary is machine-generated.

    Long-term antiarrhythmic drugs after myocardial infarction show limited benefit for preventing sudden death. Diphenylhydantoin is unsuitable, procainamide has safety concerns, but alprenolol warrants further study.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The new genetics: legal and ethical implications for medicine.

    The Medical journal of Australia·1997
    Same author

    Privacy and medical research: most people support current practice.

    The Medical journal of Australia·1990
    Same author

    Ethics, law and resources at the growing edge of medicine.

    Australian and New Zealand journal of medicine·1990
    Same author

    The university medical presence in hospitals seventy years after Flexner and a look ahead.

    Australian and New Zealand journal of medicine·1983
    Same author

    Blood pressure and westernization--hypotheses bearing on the control of hypertension.

    Contributions to nephrology·1982
    Same author

    Down with high blood pressure.

    The Medical journal of Australia·1978

    Area of Science:

    • Cardiology
    • Pharmacology
    • Clinical Trials

    Background:

    • Myocardial infarction (MI) survivors face a high risk of sudden cardiac death.
    • Antiarrhythmic drugs are explored for long-term prophylaxis post-MI.
    • Controlled trials investigate the efficacy and safety of these medications.

    Purpose of the Study:

    • To review controlled trials of long-term antiarrhythmic drug use after myocardial infarction.
    • To evaluate the potential of diphenylhydantoin, alprenolol, and procainamide in preventing sudden death.
    • To assess the feasibility of widespread prophylactic use of these agents.

    Main Methods:

    • Review of controlled clinical trial reports.
    • Analysis of data on diphenylhydantoin, alprenolol, and procainamide.

    Related Experiment Videos

  • Assessment of drug efficacy, adverse reactions, and large-scale applicability.

    • Main Results:

    • Diphenylhydantoin is deemed unsuitable for widespread prophylactic use.
    • Procainamide's large-scale evaluation is hindered by frequent serious adverse reactions.
    • Alprenolol and comparable beta-blockers show potential for extended trials.

    Conclusions:

    • Widespread prophylactic use of antiarrhythmic drugs for sudden death prevention post-MI is unlikely to be beneficial.
    • Alprenolol or similar beta-blocking agents may be suitable for further investigation.
    • Current evidence suggests limited value for non-specific long-term antiarrhythmic therapy in preventing out-of-hospital sudden coronary death.